12.1 Domain-by-Domain Quick Review
Key Takeaways
- The six PTCB Hazardous Drug Management domains are weighted 22% Engineering Controls, 22% Administrative, 16% Facility Cleaning, 16% Dispensing Final Dosage Forms, 13% PPE, and 11% Transport & Receiving — Engineering Controls and Administrative alone make up 44% of the scored exam.
- An Assessment of Risk can modify engineering-control requirements only for non-compounded final-dosage-form activities (counting, weighing, repackaging) — never for compounding.
- USP <800>'s ACPH requirement is not one number: nonsterile HD compounding/storage areas need at least 12 ACPH, while the sterile ISO Class 7 buffer room needs at least 30 ACPH.
- PPE rules are task-based, not drug-based: a single chemo glove covers intact final-dosage-form handling, while compounding, administering, deactivating/decontaminating, and any tablet manipulation all require double gloving and a chemo gown.
- Cross-domain scenario questions are common — a single question can move a drug through receiving, storage, compounding, cleaning, and PPE in one narrative, and the correct answer usually depends on identifying which domain governs the specific action described.
Why This Matters for the Exam
By this point you've worked through eleven chapters and thirty-four sections covering all six official PTCB Hazardous Drug Management domains in real depth. This section doesn't introduce new material — it collapses everything you've studied into the shape the exam actually rewards: one scaled score built from 55 questions spread unevenly across six domains. A candidate who can recite Chapter 4's pressure-cascade numbers in isolation but can't connect them to Chapter 11's receiving procedures will still lose points on synthesis questions. The exam regularly borrows a scenario from one domain and asks you to apply a rule that lives in another — a PPE question wrapped inside a receiving scenario, or a cleaning question wrapped inside a compounding scenario.
The Weighted Blueprint, One More Time
| Domain | Weight | Highest-Yield Facts to Recall |
|---|---|---|
| Engineering Controls | 22% | C-PEC choice (Class II BSC Type A2/B1/B2, or a CACI, both reaching ISO Class 5) sets everything downstream. CSTDs are required during administration of antineoplastic HDs when a compatible device exists, but only recommended during compounding. The C-SEC runs negative pressure (-0.01 to -0.03 in. w.c.) with external venting, and needs a minimum of 12 ACPH for nonsterile compounding/storage space versus 30 ACPH for the sterile ISO Class 7 buffer room — two different numbers for two different rooms. |
| Administrative | 22% | An Assessment of Risk (AoR) can modify engineering-control requirements only for non-compounded final-dosage-form activities — counting, weighing, repackaging — never for actual compounding. The 2024 NIOSH list splits every drug into Table 1 (MSHI and/or NTP-known-human-carcinogen/IARC Group 1 or 2A) or Table 2 (other NIOSH hazard criteria without that carcinogen classification). The Designated Person owns SOPs, staff competency, and the hierarchy of controls. |
| Facility Cleaning | 16% | The four-step sequence — deactivation, decontamination, cleaning, disinfection — is fixed even when a drug has no validated deactivating agent (you skip straight to decontamination; you never reorder the remaining three). Wipe sampling for marker HDs runs at C-PEC/C-SEC setup and at least every 6 months after that. Trace chemo waste goes into yellow containers; bulk or RCRA-hazardous waste goes into black containers. |
| Dispensing Final Dosage Forms | 16% | High-risk oral HDs such as doxorubicin, methotrexate, and tamoxifen cannot be split or crushed outside a C-PEC, because manipulation generates particulate contamination that intact tablets don't. Counting uses dedicated equipment that never touches non-HD product, and unit-dose dispensing is preferred whenever it avoids manipulation altogether. |
| PPE | 13% | A single ASTM D6978-tested chemo glove is sufficient for counting or handling intact final dosage forms. Compounding, administering antineoplastic HDs, deactivating/decontaminating, and any manipulation (splitting, crushing) all require double gloving plus a chemo gown. Gloves and gowns run on different clocks: gloves change every 30-60 minutes, gowns every 2-3 hours (sooner if torn or contaminated). |
| Transport & Receiving | 11% | Pneumatic tubes are prohibited for any liquid or antineoplastic HD. Unpacking never happens inside the compounding buffer area — it needs its own dedicated, neutral- or negative-pressure space. A damaged or leaking container triggers the spill SOP and chain-of-custody documentation, not a routine return-to-vendor process. |
Add the six weights and you land on exactly 100% — Engineering Controls and Administrative alone account for 44% of the scored exam, so a review pass that treats all six domains equally is still under-preparing for the two heaviest ones.
How the Domains Connect
The blueprint lists six domains as if they're separate, but the exam rarely tests them in isolation. A single scenario question can move a hazardous drug through several domains in one narrative: it arrives under Transport & Receiving (checked for damage, never carried by pneumatic tube), moves into Administrative storage (segregated, negative pressure, at least 12 ACPH), gets compounded or counted under Engineering Controls/Dispensing rules (C-PEC selection, CSTD use, manipulation restrictions), generates surface contamination and waste handled under Facility Cleaning, and requires task-appropriate PPE at every step. The highest-leverage review skill for this exam is learning to identify which domain governs the specific action a question describes — not just which drug is named.
A Study-Time Gut Check
If your remaining review time is limited, spend it in this order: Engineering Controls and Administrative first (44% combined), then Facility Cleaning and Dispensing Final Dosage Forms (32% combined), then PPE and Transport & Receiving last (24% combined). Within any domain, prioritize the numeric facts — ACPH figures, pressure ranges, glove and gown change intervals, wipe-sampling frequency — because numeric facts are both the easiest to test with precision and the easiest to confuse under time pressure. Section 12.2 walks through the specific traps built around exactly these numbers.
What "Review-Level" Questions Look Like
Don't expect this chapter's quiz questions — or the real exam's later items — to read like flashcard prompts ("What is the minimum ACPH for a C-SCA?"). By the exam's later sections, and certainly in any question that draws on multiple chapters, the format shifts toward short scenarios: a technician receives a shipment, notices something, and has to decide what happens next; a wipe-sample result comes back elevated, and the question asks what the facility does now, not just what the sampling interval is. The underlying facts are exactly what you studied in Chapters 1-11 — the review layer is learning to spot which fact a scenario is actually testing when it's buried inside a story about a specific drug, task, or room. That's why practicing synthesis questions matters even after you've mastered every individual chapter: recognition speed under a scenario wrapper is a different skill from recall speed against a direct question.
A pharmacy technician is receiving a shipment containing an antineoplastic hazardous drug packaged in glass vials. The outer shipping container shows a small, unexplained dark stain, but the technician cannot yet tell whether a vial cracked in transit. Which combination of receiving, PPE, and cleaning-domain actions is correct?
A technician is asked to split methotrexate tablets to prepare a partial dose. Which fact set correctly applies?
A facility repackages a nonsterile hazardous drug into unit-dose blister packs without performing any compounding or manipulation. It wants to use an Assessment of Risk instead of building a full C-SCA. Is this permissible?
A facility's wipe-sampling results come back elevated for cyclophosphamide on a C-PEC work surface, and no manufacturer-validated deactivating agent exists for this specific drug. What is the correct next step?